Methylthioadenosine reverses brain autoimmune disease

Annals of Neurology

Volumn 60, Issue 3, 2006, Pages 323-334

  Moreno, Beatriz ^a   Hevia, Henar ^a   Santamaria, Monica ^a   Sepulcre, Jorge ^a   Muñoz, Javier ^a   García Trevijano, Elena R ^a   Berasain, Carmen ^a   Corrales, Fernando J ^a   Avila, Matias A ^a   Villoslada, Pablo ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTE; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ADULT; AGE OF ONSET; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTES; MACROPHAGES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NITRIC OXIDE SYNTHASE TYPE II; PHYTOHEMAGGLUTININS; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; THIONUCLEOSIDES;

EID: 33749488893     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20895     Document Type: Article

References (40)

1. Williams-Ashman HG, Seidenfeld J, Galletti P. Trends in the biochemical pharmacology of 5′-deoxy-5′-methylthioadenosine. Biochem Pharmacol 1982;31:277-288.
2. Avila MA, Garcia-Trevijano ER, Lu SC, et al. Methylthioadenosine. Int J Biochem Cell Biol 2004;36:2125-2130.
3. Hevia H, Varela-Rey M, Corrales FJ, et al. 5′-Methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology 2004;39:1088-1098.
4. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-1231.
5. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001;2:762-764.
6. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
7. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-189.
8. Villoslada P, Oksenberg JR, Rio J, Montalban X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2004;62:1653.
9. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
11. Villoslada P, Abel K, Heald N, et al. Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. Eur J Immunol 2001;31:2942-2950.
12. Schlenk F, Ehninger D. Observations on the metabolism of 5′-methylthioadenosine. Arch Biochem Biophys 1964;106:95-100.
13. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998;88:45-56.
14. Garcia-Trevijano ER, Martinez-Chantar ML, Latasa MU, et al. NO sensitizes rat hepatocytes to proliferation by modifying S-adenosylmethionine levels. Gastroenterology 2002;122:1355-1363.
15. Bettelli E, Nicholson LB, Kuchroo VK. IL-10, a key effector regulatory cytokine in experimental autoimmune encephalomyelitis. J Autoimmun 2003;20:265-267.
16. van Oers NS, Chen ZJ. Cell biology. Kinasing and clipping down the NF-kappa B trail. Science 2005;308:65-66.
17. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-2224.
18. Munshi R, Clanachan AS, Baer HP. 5′-Deoxy-5′- methylthioadenosine: a nucleoside which differentiates between adenosine receptor types. Biochem Pharmacol 1988;37:2085-2089.
19. Sitkovsky MV. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 2003;65:493-501.
20. Tsutsui S, Schnermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004;24:1521-1529.
21. Minguet S, Huber M, Rosenkranz L, et al. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol 2005;35:31-41.
22. Riscoe MK, Tower PA, Ferto AJ. Mechanism of action of 5′-methylthioadenosine in S49 cells. Biochem Phatmacol 1984;33:3639-3643.
23. Neumann M, Grieshammer T, Chuvpilo S, et al. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J 1995;14:1991-2004.
24. Boisvert FM, Richard S. Arginine methylation regulates the cytokine response. Mol Cell 2004;15:492-494.
25. Mowen KA, Schurter BT, Fathman JW, et al. Arginine methylation of NIP45 modulates cytokine gene expression in effector T lymphocytes. Mol Cell 2004;15:559-571.
26. Wu QL, Fu YF, Zhou WL, et al. Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression. J Pharmacol Exp Ther 2005;313:705-711.
27. Najbauer J, Aswad DW. Diversity of methyl acceptor proteins in rat pheochromocytoma (PC12) cells revealed after treatment with adenosine dialdehyde. J Biol Chem 1990;265:12717-12721.
28. Klotz L, Schmidt M, Giese T, et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005;175:4948-4955.
29. Simile MM, Banni S, Angioni E, et al. 5′-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 2001;34:386-394.
30. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004;173:5794-5800.
31. Richard S, Morel M, Cleroux P. Arginine methylation regulates IL-2 gene expression: a role for protein arginine methyltransferase 5 (PRMT5). Biochem J 2005;388(pt 1):379-386.
32. Mekala DJ, Alli RS, Geiger TL. IL-10-dependent suppression of experimental allergic encephalomyelitis by Th2-differentiated, anti-TCR redirected T lymphocytes. J Immunol 2005;174:3789-3797.
33. Majumdar S, Aggarwal BB. Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 2003;22:1206-1218.
34. Avila MA, Berasain C, Prieto J, et al. Influence of impaired liver methionine metabolism on the development of vascular disease and inflammation. Curr Med Chem Cardiovasc Hematol Agents 2005;3:267-281.
35. Blanchet F, Cardona A, Letimier FA, et al. CD28 costimulatory signal induces protein arginine methylation in T cells. J Exp Med 2005;202:371-377.
36. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999;22:219-240.
37. Schwartz M, Shaked I, Fisher J, et al. Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci 2003;26:297-302.
38. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002;3:216-227.
39. Stramentinoli G, Gennari F. Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle. Stramentinoli patent 4,454,122. Filed: Aug 6, 1982; Issued: Jun 12, 1984.
40. Moratti E. Pharmaceutical compositions containing 5′-deoxy- 5′-methylthioadenosine s-adenosylmethionine and their salts for reducing seborrhea. Moratti patent 5,753,213. Filed Mar 13, 1990; Issued May 19, 1998.